DNA Link, Amplicon Express in Genomics Partnership
News Nov 15, 2016
DNA Link, Inc. and Amplicon Express announced that they established an agreement today for a strategic partnership for the delivery of the best quality genomics solutions. This strategic partnership will further strengthen the cooperative relationship between two companies, which have developed over the past several years. DNA Link and Amplicon Express have agreed to cooperate in areas including nucleic acid extraction, library preparation, and PacBio sequencing.
Under the terms Amplicon Express will extract HMW DNA samples of NGS-quality from crude materials such as bacteria, plants, animals and humans. These samples will be then forwarded to DNA Link to be made into a long-inserted library ideal for PacBio sequencing for genome or transcriptome analysis by the fleet of PacBio sequencers including Sequel and RSII units at DNA Link.
Jongeun Lee, CEO and the founder of DNA Link said, "Amplicon Express is an expert in nucleic acid extraction and library preparation with a long proven track of success, and DNA Link is one of the best sequencing facility that has the most experience with PacBio sequencers. This partnership will bring a tremendous synergy, and the researchers will enjoy the best quality of sequence data using the third-generation sequencers."
Robert Bogden, President and founder of Amplicon Express remarked, "DNA Link is one of the few PacBio service providers that can fully realize the added value of having very long starting DNA fragments. PacBio data from DNA Link maximizes the long reads from our HMW DNA preps in 20Kb or 30Kb libraries."
Story from DNA Link, Inc. Please note: The content above may have been edited to ensure it is in keeping with Technology Networks’ style and length guidelines.
FDA Approves First Companion Diagnostic Test to Simultaneously Screen for Multiple Non-Small Cell Lung Cancer TherapiesNews
Oncomine Dx Target Test returns results in days, helping physicians rapidly develop treatment plans for the most common form of lung cancer.
BMS, QIAGEN Partner to Develop Gene Expression Profiles for Immuno-OncologyNews
QIAGEN and Bristol-Myers Squibb intend to develop GEPs for several Bristol-Myers Squibb I-O molecules under the initial agreement.READ MORE
Comments | 0 ADD COMMENT
3rd World Congress on Human Genetics & Genetic Disorders
Oct 20 - Oct 21, 2017